menu
    • menu
    [{"orgOrder":0,"company":"PsychoGenics","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"KAR-501","moa":"Muscarinic receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"PsychoGenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"PsychoGenics \/ Karuna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PsychoGenics \/ Karuna Therapeutics"},{"orgOrder":0,"company":"PsychoGenics","sponsor":"IAMA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"PsychoGenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"PsychoGenics \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"PsychoGenics \/ PsychoGenics"},{"orgOrder":0,"company":"PsychoGenics","sponsor":"SBIR Grant","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"PsychoGenics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"PsychoGenics \/ SBIR Grant","highestDevelopmentStatusID":"2","companyTruncated":"PsychoGenics \/ SBIR Grant"},{"orgOrder":0,"company":"PsychoGenics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"RO7117997","moa":"","graph1":"Sleep","graph2":"Preclinical","graph3":"PsychoGenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"PsychoGenics \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"PsychoGenics \/ PsychoGenics"}]

    Find Clinical Drug Pipeline Developments & Deals by PsychoGenics

    Menu

    PsychoGenics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PsychoGenics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            PsychoGenics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RO7117997

                            Therapeutic Area : Sleep

                            Study Phase : Preclinical

                            Recipient : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsyc...

                            Details : Under the agreement, Roche obtains global development, manufacturing, and commercialization rights to RO7117997, an IND-ready ENT1 inhibitor discovered using the PsychoGenics’ AI-enabled phenotypic screening platforms.

                            Brand Name : RO7117997

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 01, 2023

                            Lead Product(s) : RO7117997

                            Therapeutic Area : Sleep

                            Highest Development Status : Preclinical

                            Recipient : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PsychoGenics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            PsychoGenics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery

                            Sponsor : SBIR Grant

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            PsychoGenics and Collaborations Pharmaceuticals Awarded a $1 M Grant to Use AI Platforms to Design New Drugs f...

                            Details : The funding will be used develop and apply machine learning (ML) tools to explore new areas of chemistry, with the ultimate aim of identifying treatments that target novel or multiple aspects of complex neuropsychiatric disorders.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery

                            Sponsor : SBIR Grant

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PsychoGenics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            PsychoGenics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : IAMA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome

                            Details : PsychoGenics will evaluate the anti-seizure efficacy of first-in-class selective-NKCC1 inhibitors, which restore the physiological hyperpolarizing and inhibitory GABAergic transmission in a preclinical model of Dravet syndrome.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 12, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : IAMA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PsychoGenics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            PsychoGenics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAR-501

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Karuna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics

                            Details : The agreement, allowed Karuna to leverage Psychogenics proprietary screening platforms, which utilize computer vision and machine learning to identify and evaluate new drug candidates including KAR-501 to further its pipeline of differentiated neuropsych...

                            Brand Name : KAR-501

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 11, 2022

                            Lead Product(s) : KAR-501

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Karuna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth